Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS
Ossenkoppele, G. J., Breems, D. A., Stuessi, G., van Norden, Y., Bargetzi, M., Biemond, B. J., A von dem Borne, P., Chalandon, Y., Cloos, J., Deeren, D., Fehr, M., Gjertsen, B., Graux, C., Huls, G., JJournal:
Leukemia
DOI:
10.1038/s41375-020-0725-0
Date:
February, 2020
File:
PDF, 838 KB
2020